Osteoporosis

Percentage of Patients Treated with Denosumab Who Had Vitamin D and Calcium Testing Prior to Injection (2012-2020)

Percentage of Patients Treated with Denosumab Who Had Vitamin D and Calcium Testing Prior to Injection (N=11458)

2012-2019

Denosumab is a treatment for osteoporosis given as an injection every 6 months. It has been associated with hypocalcemia, which is more common in patients with preinjection hypocalcemia and vitamin D deficiency. Serum calcium and vitamin D testing are suggested within the preceding year to reduce the risk of hypocalcemia: 70.7%, 81.0%, and 94.9% of patients had serum calcium testing in the preceding 90, 180, and 365 days, respectively, while 57.7%, 67.8%, and 88.2% of patients had vitamin D testing in the preceding 90, 180, and 365 days, respectively.